Telomere shortening and expression of TRF1 and TRF2 in uterine leiomyoma

Oh,Bong-Kyeong; Choi,Yoojung; Choi,Joong Sub

doi:10.3892/mmr.2021.12243

Telomere shortening and expression of TRF1 and TRF2 in uterine leiomyoma

Authors:
- Bong-Kyeong Oh
- Yoojung Choi
- Joong Sub Choi
View Affiliations

Affiliations: Institute for the Integration of Medicine and Innovative Technology, Hanyang University College of Medicine, Seoul 04763, Republic of Korea, Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
Published online on: June 24, 2021 https://doi.org/10.3892/mmr.2021.12243
Article Number: 606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Uterine leiomyoma is a benign smooth muscle tumor of the uterus that can exhibit histopathological traits that mimic malignancy. Telomere shortening is an early event in tumorigenesis and telomerase activation facilitates tumor progression later in the course of carcinogenesis. Telomeric repeat‑binding factor (TRF)1 and TRF2 protect telomeres, and their gene expression levels are dysregulated in various cancer types. However, the roles of telomeres and telomere protection proteins in uterine leiomyoma remain largely unknown. In this study, telomere length and the mRNA levels of various telomere‑related genes in normal tissues and leiomyoma were determined, and their relationships were evaluated. Uterine leiomyoma and normal myometrium were surgically obtained from 18 and 13 patients, respectively. Telomere length and gene expression were determined by Southern blot analysis and reverse transcription‑quantitative PCR, respectively. In matched samples, telomeres were consistently shorter in leiomyoma tissue than in adjacent normal tissue. TRF1, TRF2, PIN2‑interacting telomerase inhibitor 1 (PINX1), and telomerase RNA component were expressed at comparable levels in both leiomyoma and normal tissues. None of these genes were associated with telomere length in leiomyoma. All tested tissues were negative for telomerase reverse transcriptase, which encodes the catalytic component of telomerase, indicating that cells in uterine leiomyoma were not immortalized. In summary, telomere erosion, which reflects active proliferation during tumor evolution, was evident in uterine leiomyoma. Steady‑state expression of TRF1, TRF2 and PINX1 may be important for maintenance of telomere integrity in leiomyoma, where telomere length is shortened.

View Figures

View References

1	Bulun SE: Uterine fibroids. N Engl J Med. 369:1344–1355. 2013. View Article : Google Scholar : PubMed/NCBI
2	Al-Hendy A, Myers ER and Stewart E: Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 35:473–480. 2017. View Article : Google Scholar : PubMed/NCBI
3	de Lange T: Shelterin-Mediated Telomere Protection. Annu Rev Genet. 52:223–247. 2018. View Article : Google Scholar : PubMed/NCBI
4	Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
5	Shay JW and Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer Biol. 21:349–353. 2011. View Article : Google Scholar : PubMed/NCBI
6	Counter CM, Hirte HW, Bacchetti S and Harley CB: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA. 91:2900–2904. 1994. View Article : Google Scholar : PubMed/NCBI
7	Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T and Ishikawa F: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 18:65–68. 1998. View Article : Google Scholar : PubMed/NCBI
8	Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56:645–650. 1996.PubMed/NCBI
9	van Steensel B and de Lange T: Control of telomere length by the human telomeric protein TRF1. Nature. 385:740–743. 1997. View Article : Google Scholar : PubMed/NCBI
10	van Steensel B, Smogorzewska A and de Lange T: TRF2 protects human telomeres from end-to-end fusions. Cell. 92:401–413. 1998. View Article : Google Scholar : PubMed/NCBI
11	Oh BK, Kim YJ, Park C and Park YN: Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 166:73–80. 2005. View Article : Google Scholar : PubMed/NCBI
12	Pal D, Sharma U, Singh SK, Kakkar N and Prasad R: Over-expression of telomere binding factors (TRF1 & TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration invitro. PLoS One. 10:e01156512015. View Article : Google Scholar : PubMed/NCBI
13	Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E, Koering CE and Gilson E: Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res. 9:1105–1111. 2003.PubMed/NCBI
14	Grun LK, Teixeira ND Jr, Mengden LV, de Bastiani MA, Parisi MM, Bortolin R, Lavandoski P, Pierdoná V, Alves LB, Moreira JC, et al: TRF1 as a major contributor for telomeres' shortening in the context of obesity. Free Radic Biol Med. 129:286–295. 2018. View Article : Google Scholar : PubMed/NCBI
15	Saito K, Yagihashi A, Nasu S, Izawa Y, Nakamura M, Kobayashi D, Tsuji N and Watanabe N: Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res. 93:253–258. 2002. View Article : Google Scholar : PubMed/NCBI
16	Schneider RP, Garrobo I, Foronda M, Palacios JA, Marión RM, Flores I, Ortega S and Blasco MA: TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. Nat Commun. 4:19462013. View Article : Google Scholar : PubMed/NCBI
17	Bejarano L, Schuhmacher AJ, Méndez M, Megías D, Blanco-Aparicio C, Martínez S, Pastor J, Squatrito M and Blasco MA: Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts. Cancer Cell. 32:590–607.e4. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhou XZ, Huang P, Shi R, Lee TH, Lu G, Zhang Z, Bronson R and Lu KP: The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest. 121:1266–1282. 2011. View Article : Google Scholar : PubMed/NCBI
19	Deng W, Jiao N, Li N, Wan X, Luo S and Zhang Y: Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy. Biomed Pharmacother. 73:1–5. 2015. View Article : Google Scholar : PubMed/NCBI
20	Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, et al: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci. 101:1543–1549. 2010. View Article : Google Scholar : PubMed/NCBI
21	Qian D, Zhang B, He LR, Cai MY, Mai SJ, Liao YJ, Liu YH, Lin MC, Bian XW, Zeng YX, et al: The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas. J Pathol. 229:765–774. 2013. View Article : Google Scholar : PubMed/NCBI
22	Bai J, Chen YS, Mei PJ, Liu QH, Du Y and Zheng JN: PinX1 is up-regulated and associated with poor patients' survival in gliomas. Int J Clin Exp Pathol. 8:6952–6959. 2015.PubMed/NCBI
23	Oliva E, Carcangiu M, Carinelli SG, Ip P, Loening T and Longacre TA: Mesenchymal tumours. WHO Classification of Tumours of Female Reproductive Organs. 4th edition. Kurman RJ, Carcangiu ML, Herrington CS and Young RH: IARC Press; Lyon: pp. 135–138. 2014
24	Bonatz G, Frahm SO, Andreas S, Heidorn K, Jonat W and Parwaresch R: Telomere shortening in uterine leiomyomas. Am J Obstet Gynecol. 179:591–596. 1998. View Article : Google Scholar : PubMed/NCBI
25	Rogalla P, Rohen C, Hennig Y, Deichert U, Bonk U and Bullerdiek J: Telomere repeat fragment sizes do not limit the growth potential of uterine leiomyomas. Biochem Biophys Res Commun. 211:175–182. 1995. View Article : Google Scholar : PubMed/NCBI
26	Kruk PA, Rampino NJ and Bohr VA: DNA damage and repair in telomeres: Relation to aging. Proc Natl Acad Sci USA. 92:258–262. 1995. View Article : Google Scholar : PubMed/NCBI
27	Scheibe M, Arnoult N, Kappei D, Buchholz F, Decottignies A, Butter F and Mann M: Quantitative interaction screen of telomeric repeat-containing RNA reveals novel TERRA regulators. Genome Res. 23:2149–2157. 2013. View Article : Google Scholar : PubMed/NCBI
28	Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 451:141–146. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, Olsen JC, Miller SW, Weinberg RA, et al: Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 21:4577–4586. 2002. View Article : Google Scholar : PubMed/NCBI
30	Deng Z, Wang Z, Stong N, Plasschaert R, Moczan A, Chen HS, Hu S, Wikramasinghe P, Davuluri RV, Bartolomei MS, et al: A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J. 31:4165–4178. 2012. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Jeffreys AJ, Wilson V and Thein SL: Hypervariable ‘minisatellite’ regions in human DNA. Nature. 314:67–73. 1985. View Article : Google Scholar : PubMed/NCBI
33	Karlseder J, Broccoli D, Dai Y, Hardy S and de Lange T: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1321–1325. 1999. View Article : Google Scholar : PubMed/NCBI
34	Celli GB and de Lange T: DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol. 7:712–718. 2005. View Article : Google Scholar : PubMed/NCBI
35	Martínez P, Thanasoula M, Muñoz P, Liao C, Tejera A, McNees C, Flores JM, Fernández-Capetillo O, Tarsounas M and Blasco MA: Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 23:2060–2075. 2009. View Article : Google Scholar
36	Zhou XZ and Lu KP: The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 107:347–359. 2001. View Article : Google Scholar : PubMed/NCBI
37	Laganà AS, Vergara D, Favilli A, La Rosa VL, Tinelli A, Gerli S, Noventa M, Vitagliano A, Triolo O, Rapisarda AM, et al: Epigenetic and genetic landscape of uterine leiomyomas: A current view over a common gynecological disease. Arch Gynecol Obstet. 296:855–867. 2017. View Article : Google Scholar
38	Yang Q, Mas A, Diamond MP and Al-Hendy A: The mechanism and function of epigenetics in uterine leiomyoma development. Reprod Sci. 23:163–175. 2016. View Article : Google Scholar : PubMed/NCBI
39	Cawthon RM: Telomere measurement by quantitative PCR. Nucleic Acids Res. 30:e472002. View Article : Google Scholar : PubMed/NCBI
40	Tarik M, Ramakrishnan L, Sachdev HS, Tandon N, Roy A, Bhargava SK and Pandey RM: Validation of quantitative polymerase chain reaction with Southern blot method for telomere length analysis. Future Sci OA. 4:FSO2822018. View Article : Google Scholar : PubMed/NCBI
41	Sun Y, Zhang L, Zhao L, Wu X and Gu J: Association of leukocyte telomere length in peripheral blood leukocytes with endometrial cancer risk in Caucasian Americans. Carcinogenesis. 36:1327–1332. 2015. View Article : Google Scholar : PubMed/NCBI
42	Benati M, Montagnana M, Danese E, Mazzon M, Paviati E, Garzon S, Laganà AS, Casarin J, Giudici S, Raffaelli R, et al: Aberrant telomere length in circulating cell-free DNA as possible blood biomarker with high diagnostic performance in endometrial cancer. Pathol Oncol Res. 26:2281–2289. 2020. View Article : Google Scholar : PubMed/NCBI
43	Blasco MA, Rizen M, Greider CW and Hanahan D: Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet. 12:200–204. 1996. View Article : Google Scholar : PubMed/NCBI
44	Yashima K, Milchgrub S, Gollahon LS, Maitra A, Saboorian MH, Shay JW and Gazdar AF: Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res. 4:229–234. 1998.PubMed/NCBI
45	Yi X, Tesmer VM, Savre-Train I, Shay JW and Wright WE: Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol. 19:3989–3997. 1999. View Article : Google Scholar : PubMed/NCBI
46	Gazzaniga FS and Blackburn EH: An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity. Blood. 124:3675–3684. 2014. View Article : Google Scholar : PubMed/NCBI